In this briefing: Aditya Birla Capital (ABCAP IN): Global Index Inclusion & Big Impact HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... Healthcare Global Enterprises Ltd - Guiding Steady Growth Ahead Jyothy Labs Ltd - Volumes Drive a Steady Quarter; Maintain HOLD Mahanagar Gas Ltd - Largely Inline Q3; Volume Growth on Track 1. Aditya Birla Capital (ABCAP IN): Global Index Inclusion & Big Impact Aditya Birla Capital Ltd (ABCAP IN) will be added to a global index later this month and passive trackers will need to buy a significant number of days of ADV. The impact in terms of delivery volume to buy is much higher and the stock looks underpositioned relative to the estimated passive buying. Aditya Birla Capital Ltd (ABCAP IN) could outperform peers in the short-term and there will be profit taking closer to implementation of the changes. 2. HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... BSE: BSE delivered a strong quarter with revenue rising 16.4% QoQ and 60.8% YoY, led by sustained traction in transaction revenue and strong book-building and listing fees Adjusted PAT (ex-labor laws provision, additional SGF, and impairment) came in at INR 6.5bn vs our estimate of INR 6.2bn Transaction revenue, contributing 77% of total revenue, surged 26% QoQ on continued gains in options market share and recovery in industry volumes Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... Healthcare Global Enterprises Ltd - Guiding Steady Growth Ahead Jyothy Labs Ltd - Volumes Drive a Steady Quarter; Maintain HOLD Mahanagar Gas Ltd - Largely Inline Q3; Volume Growth on Track Embassy Office Parks REIT Ltd - Q3FY26: Strategic Expansion and Rental Upside to Drive Growth 1. HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... BSE: BSE delivered a strong quarter with revenue rising 16.4% QoQ and 60.8% YoY, led by sustained traction in transaction revenue and strong book-building and listing fees Adjusted PAT (ex-labor laws provision, additional SGF, and impairment) came in at INR 6.5bn vs our estimate of INR 6.2bn Transaction revenue, contributing 77% of total revenue, surged 26% QoQ on continued gains in options market share and recovery in industry volumes Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Wakefit Innovations Ltd IPO- Forensic Analysis India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% India: Goldilocks Gives Way to Constraints Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Healthcare Global Enterprises Ltd - 5 Th December, 2025 1. Wakefit Innovations Ltd IPO- Forensic Analysis Wakefit Innovations (1684049D IN) 's INR 12.9 bn IPO is a combination of fresh issue worth INR 3.8 bn and OFS component worth INR 9.1 bn. Wakefit is among the top 3 companies in the organised mattress market and has been growing much faster than its rival B2C companies. Wakefit’s turnaround in profitability in H1FY26 however relies on other income, inventory changes and A&P spends. Moreover, stagnant provisions for loyalty, and slow moving inventory warrant attention 2. India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% RBI's MPC cut 25bp as expected, but it remains behind the curve, with the real policy rate now excessively high at +5%.

In this briefing: India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% India: Goldilocks Gives Way to Constraints Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Healthcare Global Enterprises Ltd - 5 Th December, 2025 Sedemac Mechatronics Ltd Pre-IPO Tearsheet 1. India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% RBI's MPC cut 25bp as expected, but it remains behind the curve, with the real policy rate now excessively high at +5%. RBI inflation forecasts were and remain too high. Food deflation is likely to be shortlived, with vegetable prices rising MoM since May'25. But all other food and non-food inflation components are moderating, and GST cuts impart further disinflation. We expect inflation to be 1.8%YoY in Q4FY26 (vs RBI's 2.9%YoY forecast), 2.3% and 2.5% in Q1 and Q2FY27, so expect another 75bp reduction in repo rate by Aug'26. 2. India: Goldilocks Gives Way to Constraints RBI cuts repo rate by 25bps to 5.25% as expected, citing exceptional disinflation (0.25% October CPI) and 8.2% growth, though maintaining a neutral stance signals easing cycle may be nearing end.

In this briefing: India: Goldilocks Gives Way to Constraints Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Healthcare Global Enterprises Ltd - 5 Th December, 2025 Sedemac Mechatronics Ltd Pre-IPO Tearsheet Exencial Industry Tidings 05/12/2025 1. India: Goldilocks Gives Way to Constraints RBI cuts repo rate by 25bps to 5.25% as expected, citing exceptional disinflation (0.25% October CPI) and 8.2% growth, though maintaining a neutral stance signals easing cycle may be nearing end. It forecasts headline inflation to fall to 0.6% in Q3 before rebounding sharply to 2.9% and 3.9% subsequently, limiting the scope for additional rate cuts despite growth moderating from current highs. Durable liquidity injections alongside rate cuts acknowledge monetary transmission constraints. The consensus sees 5.25% as the terminal rate, with policy dependent on inflation normalisation and external sector stability. This content is sourced through publicly available sources and has been machine generated.

In this briefing: Halyk Bank — 7% NIM likely to be sustained into 2026 Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Zoomlion (1157 HK/000157 CH) - Expect Accelerated Sales Growth in Nov Healthcare Global Enterprises Ltd - 5 Th December, 2025 Imdex (IMD): Reading the Strata 1. Halyk Bank — 7% NIM likely to be sustained into 2026 Halyk Bank reported a 13.8% y-o-y increase in net interest income in Q325 with a sustained high net interest margin (NIM) of 7.1% versus 7.3% in Q324 and robust loan book growth of 19.7% y-o-y (8.2% ytd). Combined with good cost discipline (the cost-to-income ratio (CIR) was 16.3% in Q325 vs 16.1% in Q324), this allowed the company to maintain an ROE above 30% (34.3% in Q325 on an annualised basis). Halyk preserved a strong capital base with a CET-1, Tier-1 and total capital ratio of 17.4% at end-September 2025 (with an indicative FY26e target of 17–19%) and local capital ratios of 18.3% versus the regulatory requirement for total capital (k2) of 12.0%.

In this briefing: Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Healthcare Global Enterprises Ltd - 5 Th December, 2025 Sedemac Mechatronics Ltd Pre-IPO Tearsheet Exencial Industry Tidings 05/12/2025 Milestone Gears Ltd Pre-IPO Tearsheet 1. Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Wakefit Innovations' INR 1,288.89 crore IPO signaling the pivot of India's largest D2C home brand toward institutional funding for accelerated omnichannel expansion . The fund utilization is heavily skewed towards offline growth and brand building, confirming a strategic shift from pure-play digital to a capital-intensive, integrated retail model. While the model mitigates supply chain risk through vertical integration , we must weigh the past profitability volatility and strategic roadmap for capturing India's rapidly formalizing home and furnishings sector . 2. Healthcare Global Enterprises Ltd - 5 Th December, 2025 HCG’s management hosted an investor and analyst interaction where the new CEO, Mr.

In this briefing: Healthcare Global Enterprises Ltd - 5 Th December, 2025 Sedemac Mechatronics Ltd Pre-IPO Tearsheet Exencial Industry Tidings 05/12/2025 Milestone Gears Ltd Pre-IPO Tearsheet Primer: Wakefit Innovations (1684049D IN) - Dec 2025 1. Healthcare Global Enterprises Ltd - 5 Th December, 2025 HCG’s management hosted an investor and analyst interaction where the new CEO, Mr. Manish Mattoo (a practicing anaesthesiologist and MBA in Finance), outlined a clear four-pillar strategy centered on clinical outcomes, profitable growth, capital efficiency, and patient experience. There will be a shift in the reporting framework from the “mature vs. new” category to regional clusters and oncology-appropriate KPIs such as ARPP and patient volumes. The medium-term aspiration is to grow ahead of the industry, improve EBITDA margins beyond the historical CAGR, and uplift company-level ROCE to 20% as more centres mature. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

New Delhi, Cancer focused healthcare service provider Healthcare Global Enterprises has reported an … to Indian genetic diversity," HealthCare Global Enterprises (HCG) Founder and …